# 2.2 ANALYSIS OF COMPANY SPONSORED CLINICAL TRIALS

**Page range:** 19â€“19

```text
2.2
ANALYSIS OF COMPANY SPONSORED CLINICAL TRIALS
Pralsetinib is being investigated for use in the treatment of patients with RET fusion
positive NSCLC, RET-altered thyroid cancer, and other RET fusion-positive solid tumors.
As of 3-Sept-2024, the clinical development program for pralsetinib consists of 8 ongoing
company sponsored interventional trials (see Table 1 for an overview of these clinical
trials).
Table 1
Overview of Company Sponsored Interventional Trials for
Pralsetinib
Study
Number
Study Title
Study
Phase
Study Design
[Randomisation,
Blinding, Design,
Comparison]
BO41932
Tumor-agnostic precision immuno-oncology
and somatic targeting rational for you
(TAPISTRY) phase II platform trial
Phase II
```